Brexpiprazole

FDA Approved: * February 3, 2023
Pharm Company: * AJANTA PHARMA LTD
Category: Antipsychotic

Brexpiprazole, sold under the brand name Rexulti among others, is an atypical antipsychotic. It is a dopamine D2 receptor partial agonist and has been described as a "serotonin–dopamine activity modulator" (SDAM). The drug was approved by the U.S. Food and Drug Administration (FDA) on July 10, 2015, for the treatment of schizophrenia, and as an adjunctive treatment for depression.[4][5] It has been designed to provide improved efficacy and tolerability (e... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Brexpiprazole .25 mg Oral Tablet
NDC: 27241-204
Labeler:
Ajanta Pharma USA Inc.
Brexpiprazole .5 mg Oral Tablet
NDC: 27241-205
Labeler:
Ajanta Pharma USA Inc.
Brexpiprazole 1 mg Oral Tablet
NDC: 27241-206
Labeler:
Ajanta Pharma USA Inc.
Brexpiprazole 2 mg Oral Tablet
NDC: 27241-207
Labeler:
Ajanta Pharma USA Inc.
Brexpiprazole 3 mg Oral Tablet
NDC: 27241-208
Labeler:
Ajanta Pharma USA Inc.
Brexpiprazole 4 mg Oral Tablet
NDC: 27241-209
Labeler:
Ajanta Pharma USA Inc.
Brexpiprazole .25 mg Oral Tablet, Film Coated
NDC: 31722-434
Labeler:
Camber Pharmaceuticals, Inc.
Brexpiprazole .5 mg Oral Tablet, Film Coated
NDC: 31722-435
Labeler:
Camber Pharmaceuticals, Inc.
Brexpiprazole 1 mg Oral Tablet, Film Coated
NDC: 31722-436
Labeler:
Camber Pharmaceuticals, Inc.
Brexpiprazole 2 mg Oral Tablet, Film Coated
NDC: 31722-437
Labeler:
Camber Pharmaceuticals, Inc.

Related Brands

Drugs with the same active ingredients